



Medical Policy

Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease

Table of Contents

- [Policy: Commercial](#)
- [Description](#)
- [Information Pertaining to All Policies](#)
- [Authorization Information](#)
- [Policy History](#)
- [Coding Information](#)
- [References](#)

Policy Number: 016

BCBSA Reference Number: 2.04.23 (For Plans internal use only)

Related Policies

None

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Measurement of plasma levels of homocysteine is considered **NOT MEDICALLY NECESSARY** in the screening, evaluation, and management of patients for cardiovascular disease.

Measurement of plasma levels of homocysteine is considered **INVESTIGATIONAL** in the screening, evaluation, and management of patients with venous thromboembolism or risk of venous thromboembolism.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This is not a covered service.
Commercial PPO and Indemnity	This is not a covered service.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The following CPT code is considered investigational for **Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:**

CPT Codes

CPT codes:	Code Description
83090	Homocysteine

Description

Homocysteine is a sulfur-containing amino acid that is rapidly oxidized in plasma into homocysteine and cysteine-homocysteine disulfide. Measurement of total plasma homocysteine is the sum of homocysteine and its oxidized forms.

Plasma levels of homocysteine have been actively researched as a risk factor for cardiovascular disease (CVD), initially based on the observation that patients with hereditary homocystinuria, an inborn error of metabolism associated with high plasma levels of homocysteine, had a markedly increased risk of CVD. Subsequently, prospective epidemiologic studies were conducted to determine if an elevated plasma level of homocysteine was an independent risk factor for CVD and could be used to improve current risk prediction models. Several case-control studies have also suggested that elevated homocysteine is a risk factor for venous thromboembolism (VTE; pulmonary embolism, deep vein thrombosis).

Interest in homocysteine as a potentially modifiable risk factor has been stimulated by the epidemiologic finding that levels of homocysteine inversely correlate with levels of folate. This finding has raised the possibility that treatment with folic acid might lower homocysteine levels and, in turn, reduce the risk of CVD and thrombotic events. Therefore, homocysteine has a potential utility both as a risk predictor and as a target of treatment.

Determination of homocysteine concentration may be offered as a component of a comprehensive cardiovascular risk assessment that may include evaluation of small-density lipoproteins, subclassification of high-density lipoproteins, evaluation of lipoprotein (a), high-sensitivity C-reactive protein, and genotyping of apolipoprotein E. Determination of homocysteine concentration may also be offered as part of the risk assessment for patients at high-risk of VTE events or who have experienced idiopathic VTE, recurrent VTE, thrombosis occurring at a young age, or thrombosis at an unusual site.

Summary

Homocysteine is an amino acid that has been evaluated as a potential marker of cardiovascular disease (CVD) and as a potential risk marker for people with CVD and thrombotic disorders; the presence of this amino acid raises one's risk of developing a blood clot. The association between homocysteine-lowering interventions and the risk of CVD or thrombotic events has been examined.

Summary of Evidence

For individuals who are asymptomatic with the risk of CVD or individuals with CVD who receive homocysteine testing, the evidence includes observational studies and randomized controlled trials (RCTs) of homocysteine-lowering interventions. Relevant outcomes are change in disease status and morbid events such as cardiovascular (CV) events, including myocardial infarction, stroke, and CV death. Evidence from RCTs evaluating homocysteine-lowering interventions does not support the hypothesis that lowering homocysteine levels with folate and/or B vitamins improves CV outcomes. Numerous large RCTs and meta-analyses of these trials have consistently reported that homocysteine-lowering treatment is ineffective in reducing major CV events. A Cochrane systematic review found that homocysteine-lowering treatment reduced the risk of stroke. However, the investigators considered the results weak,

and the clinical significance of this reduction is still unknown. Given a large amount of evidence from placebo-controlled, randomized trials that homocysteine-lowering interventions do not improve health outcomes, it is unlikely that routine homocysteine testing has the potential to change management that improves health outcomes. The evidence is sufficient to determine that the technology is unlikely to improve the net health outcome.

For individuals who are asymptomatic with the risk of venous thromboembolism (VTE) or individuals who have experienced VTE events who receive homocysteine testing, the evidence includes observational studies and RCTs of homocysteine-lowering interventions. Relevant outcomes are change in disease status and morbid events such as VTE occurrence. Evidence from RCTs evaluating homocysteine-lowering interventions does not support the hypothesis that lowering homocysteine levels with folate and/or B vitamins reduces the risk of VTE. Only a single RCT was designed to test for VTE as a primary outcome. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

Date	Action
2/2022	Annual review. Description, summary, and references updated. Policy statements unchanged. Need for policy affirmed.
2/2021	Annual review. Description, summary, and references updated. Policy statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference.
1/2020	Annual review. Description, summary, and references updated. Policy statements unchanged.
2/2019	Annual review. Description, summary, and references updated. Policy statements unchanged.
5/2017	Annual review. New not medically necessary and investigational indications described. Title changed. New references added. Effective 5/1/2017.
1/2016	Annual review. New references added
8/2015	Added coding language.
6/2015	Annual review. New references added
7/2014	Annual review. New references added
5/2013	Annual review. New references added
11/2011- 4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
4/2011	Reviewed - Medical Policy Group – Cardiology and Pulmonology. No changes to policy statements.
4/2010	Reviewed - Medical Policy Group - Cardiology. No changes to policy statements.
4/2009	Reviewed - Medical Policy Group – Cardiology. No changes to policy statements.
4/2008	Reviewed - Medical Policy Group -Cardiology. No changes to policy statements.
3/2008	New Policy effective 3/2008 describing ongoing non-coverage.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Veeranna V, Zalawadiya SK, Niraj A, et al. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol. Aug 30 2011; 58(10): 1025-33. PMID 21867837

2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA*. Oct 2002; 288(16): 2015-22. PMID 12387654
3. Shoamanesh A, Preis SR, Beiser AS, et al. Circulating biomarkers and incident ischemic stroke in the Framingham Offspring Study. *Neurology*. Sep 20 2016; 87(12): 1206-11. PMID 27558379
4. Han L, Wu Q, Wang C, et al. Homocysteine, Ischemic Stroke, and Coronary Heart Disease in Hypertensive Patients: A Population-Based, Prospective Cohort Study. *Stroke*. Jul 2015; 46(7): 1777-86. PMID 26038522
5. Shi Z, Guan Y, Huo YR, et al. Elevated Total Homocysteine Levels in Acute Ischemic Stroke Are Associated With Long-Term Mortality. *Stroke*. Sep 2015; 46(9): 2419-25. PMID 26199315
6. Wang C, Han L, Wu Q, et al. Association between homocysteine and incidence of ischemic stroke in subjects with essential hypertension: a matched case-control study. *Clin Exp Hypertens*. 2015; 37(7): 557-62. PMID 25992490
7. Park CS, Ihm SH, Yoo KD, et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. *Am J Cardiol*. May 01 2010; 105(9): 1284-8. PMID 20403480
8. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med*. May 13 1999; 340(19): 1449-54. PMID 10320382
9. Marti-Carvajal AJ, Sola I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev*. Aug 17 2017; 8: CD006612. PMID 28816346
10. Marti-Carvajal AJ, Sola I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev*. Jan 31 2013; (1): CD006612. PMID 23440809
11. Marti-Carvajal AJ, Sola I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev*. Jan 15 2015; 1: CD006612. PMID 25590290
12. Park JH, Saposnik G, Ovbiagele B, et al. Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: A meta-analysis. *Int J Stroke*. Feb 2016; 11(2): 206-11. PMID 26783312
13. Yi X, Zhou Y, Jiang D, et al. Efficacy of folic acid supplementation on endothelial function and plasma homocysteine concentration in coronary artery disease: A meta-analysis of randomized controlled trials. *Exp Ther Med*. May 2014; 7(5): 1100-1110. PMID 24940394
14. Liu Y, Tian T, Zhang H, et al. The effect of homocysteine-lowering therapy with folic acid on flow-mediated vasodilation in patients with coronary artery disease: a meta-analysis of randomized controlled trials. *Atherosclerosis*. Jul 2014; 235(1): 31-5. PMID 24814647
15. Huang T, Chen Y, Yang B, et al. Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. *Clin Nutr*. Aug 2012; 31(4): 448-54. PMID 22652362
16. Zhou YH, Tang JY, Wu MJ, et al. Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis. *PLoS One*. 2011; 6(9): e25142. PMID 21980387
17. Clarke R, Halsey J, Bennett D, et al. Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. *J Inherit Metab Dis*. Feb 2011; 34(1): 83-91. PMID 21069462
18. van Dijk SC, Enneman AW, Swart KM, et al. Effects of 2-year vitamin B12 and folic acid supplementation in hyperhomocysteinemic elderly on arterial stiffness and cardiovascular outcomes within the B-PROOF trial. *J Hypertens*. Sep 2015; 33(9): 1897-906; discussion 1906. PMID 26147383
19. Armitage JM, Bowman L, Clarke RJ, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. *JAMA*. Jun 23 2010; 303(24): 2486-94. PMID 20571015
20. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med*. Apr 13 2006; 354(15): 1567-77. PMID 16531613
21. Bonna KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med*. Apr 13 2006; 354(15): 1578-88. PMID 16531614
22. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. *J Thromb Haemost*. Feb 2005; 3(2): 292-9. PMID 15670035
23. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. *Arch Intern Med*. Oct 26 1998; 158(19): 2101-6. PMID 9801176

24. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. *Thromb Haemost.* Dec 1998; 80(6): 874-7. PMID 9869152
25. Naess IA, Christiansen SC, Romundstad PR, et al. Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population--results from the HUNT 2 study. *Br J Haematol.* May 2008; 141(4): 529-35. PMID 18318759
26. Zhou K, Zhao R, Geng Z, et al. Association between B-group vitamins and venous thrombosis: systematic review and meta-analysis of epidemiological studies. *J Thromb Thrombolysis.* Nov 2012; 34(4): 459-67. PMID 22743781
27. den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. *Blood.* Jan 01 2007; 109(1): 139-44. PMID 16960155
28. Ray JG, Kearon C, Yi Q, et al. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. *Ann Intern Med.* Jun 05 2007; 146(11): 761-7. PMID 17470822
29. National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification [CG181]. 2016; <https://www.nice.org.uk/guidance/cg181/chapter/1-Recommendations#identifying-and-assessing-cardiovascular-disease-cvd-risk-2>. Accessed October 16, 2020.
30. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* Dec 2014; 45(12): 3754-832. PMID 25355838
31. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation.* Sep 10 2019; 140(11): e596-e646. PMID 30879355
32. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation.* Mar 21 2017; 135(12): e726-e779. PMID 27840333
33. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* Jul 01 2014; 63(25 Pt B): 2935-2959. PMID 24239921
34. Myers GL, Christenson RH, Cushman M, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. *Clin Chem.* Feb 2009; 55(2): 378-84. PMID 19106185
35. Maynard G. Preventing hospital-associated venous thromboembolism: a guide for effective quality improvement. 2nd ed. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
36. National Institute for Health and Care Excellence (NICE). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. [NG89]. 2018; <https://www.nice.org.uk/guidance/ng89>. Accessed October 17, 2020.
37. U.S. Preventive Services Task Force. Cardiovascular Disease: Risk Assessment Using Nontraditional Risk Factors. 2018; <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cardiovascular-disease-screening-using-nontraditional-risk-assessment>. Accessed October 16, 2020.